Scientific Advisory Board
Prof. Aimery de Gramont
Professor de Gramont joined the Scientific Advisory Board since January 2006. He has been Professor of Oncology, Saint-Antoine Hospital, Paris, France since 1993 and Chief of Services from 2001 to 2014. He is Professor and Chief of Oncology Services at Institut Hospitalier Franco Britannique, Paris since 2014. He has created two cornerstone standard of regimens (FOLFIRI and FOLFOX) for colorectal cancer, and chaired many large international trials for colorectal cancers. He is also the President and Founder of GERCOR and ARCAD Foundation in France. He received his MD from Faculty of Medicine Laureate, Paris, France.
Dr. Alain Herrera
Dr. Herrera joined the Scientific Advisory Board of PharmaEngine in November 2008. He created the Foundation of Alain Oncology Consulting in November 2008 after heading for ten years the oncology business at sanofi-aventis where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the gastric and head & neck indications for docetaxel (TAXOTERE®). He received his MD from Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France.
Clinical Advisory Board
R.K. Hsieh, M.D.
Dr. Hsieh is now Attending Physician at the Division of Hematology and Oncology of Taipei Medical University Hospital in Taiwan. He is an expert of clinical development of new drugs in colorectal cancer, breast cancer, lung cancer, prostate cancer and gastric cancer.
C.H. Wang M.D.
Dr. Wang is Director of cancer center at Chang Gung Memorial Hospital in Keelung. And his expertise is the clinical development of new drugs in gastrointestinal cancers and head & neck cancer.